SCHEMBL2454178

SCHEMBL2454178

CN1CCN(Cc2cccc(F)c2C(=O)Nc2n[nH]c3c2CN(S(=O)(=O)c2cc(F)cc(F)c2)CC3)CC1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.65
NTRK1 P04629 6/20 0.41
NTRK3 Q16288 3/20 0.41
NTRK2 Q16620 3/20 0.41
AURKA O14965 3/20 0.41
CCNA2 P20248 3/20 0.41
CDK2 P24941 3/20 0.41
CCNA1 P78396 3/20 0.41
AURKB Q96GD4 2/20 0.40
FLT3 P36888 1/20 0.40
LIMK1 P53667 1/20 0.40
LIMK2 P53671 1/20 0.40
AURKC Q9UQB9 1/20 0.40
MET P08581 2/20 0.39
EP300 Q09472 2/20 0.38
CREBBP Q92793 2/20 0.38
RBP4 P02753 1/20 0.37
HTR6 P50406 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1888330 0.94 IGF1R (0.56) IGF1RNTRK1AURKACCNA2CDK2
SCHEMBL1888347 0.93 IGF1R (0.56) IGF1RNTRK1AURKACCNA2CDK2
SCHEMBL1886720 0.92 IGF1R (0.56) IGF1RNTRK1NTRK3NTRK2AURKA
Hydrochloric Acid SCHEMBL1889383 0.91 IGF1R (0.56) IGF1RNTRK1NTRK3NTRK2AURKA
SCHEMBL1889296 0.90 IGF1R (0.59) IGF1RNTRK1AURKACCNA2CDK2
SCHEMBL1888100 0.88 IGF1R (0.58) IGF1RNTRK1AURKACCNA2CDK2
SCHEMBL1895247 0.88 IGF1R (0.57) IGF1RNTRK1AURKACCNA2CDK2
SCHEMBL1886319 0.87 IGF1R (0.49) IGF1RNTRK1NTRK3NTRK2CCNA2
SCHEMBL1886130 0.85 IGF1R (0.54) IGF1RNTRK1AURKACCNA2CDK2
SCHEMBL1893615 0.84 IGF1R (0.53) IGF1RAURKACCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173659-B2 Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-05-08 US disclosed
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-09-22 US disclosed
EP-1968976-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-09-17 EP disclosed
WO-2007068619-A1 SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230470-A1 SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K3, MAP3K1, MAP3K19 IGF1R 760/4885NTRK1 1131/4885NTRK3 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.